CD39 Targeted Therapies Market By Therapy Type (Monoclonal Antibodies, Bispecific Antibodies, Small-Molecule Inhibitors); By Cancer Indication (Non-Small Cell Lung Cancer, Pancreatic Cancer, Gastrointestinal Stromal Tumors, Desmoid Tumors, Other Solid Tumors); By Treatment Approach (Monotherapy, Combination Immunotherapy, Combination Chemotherapy, Perioperative Therapy); By End User (Hospitals, Specialty Cancer Centers, Research Institutes, Clinical Trial Centers); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

CD39 Targeted Therapies Market: Biomarker Validation and Randomized Evidence Define the Commercial Race

The Global CD39 Targeted Therapies Market is estimated to reach USD 498.54 million in 2025 and is projected to grow to USD 1.48 billion by 2032, expanding at a CAGR of 16.8% during the forecast period, according to Strategic Market Research.

 

Growth is being shaped by expanding clinical investment in the ATP–adenosine pathway, increasing use of combination immunotherapy, stronger pharmaceutical partnerships, and the search for treatments that can improve outcomes in tumors with weak or incomplete responses to existing immune checkpoint inhibitors.

 

CD39-targeted therapies have yet to receive FDA approval; all candidates remain in clinical development, primarily for oncology. CD39 inhibitors aim to restore anti-tumor immunity by blocking ATP conversion into immunosuppressive adenosine, thereby enhancing immune-cell activation and improving tumor response.

 

Most pipeline programs involve monoclonal antibodies used alongside immune checkpoint inhibitors. Key candidates include TTX-030 (Eltivutabart) from AbbVie and Trishula Therapeutics, IPH5201 from Innate Pharma and AstraZeneca, ES014 from Elpiscience, and AB598 from Arcus Biosciences and Gilead, which are being evaluated across advanced cancers and combination treatment settings.

 

Combination Treatment Is the Dominant Development Strategy

Most clinical programs are positioning CD39 blockade as an additional component of an established oncology regimen rather than a standalone replacement for chemotherapy or checkpoint inhibition. IPH5201 is being studied with durvalumab and platinum-based chemotherapy in resectable non-small cell lung cancer. TTX-030 has been evaluated with gemcitabine and nab-paclitaxel, with or without the PD-1 antibody budigalimab, in metastatic pancreatic cancer. AB598 has also entered clinical evaluation in both monotherapy and combination cohorts.

This strategy gives developers access to treatment settings where existing regimens already have physician acceptance, established hospital pathways, and defined reimbursement structures. It also raises the evidence threshold. A CD39 therapy must show that its addition produces meaningful clinical benefit beyond the underlying regimen. Response-rate improvements may support development, but regulatory and commercial positioning will depend increasingly on progression-free survival, overall survival, recurrence reduction, pathological response, and treatment durability.

Combination regimens also influence pricing and adoption. Adding another biologic to chemotherapy and checkpoint inhibition increases total treatment cost, infusion complexity, and hospital resource use. Developers that can identify patient groups with a higher probability of response will be better placed to support premium pricing and payer acceptance.

 

IPH5201 Extends CD39 Development into Perioperative Lung Cancer

IPH5201, developed by Innate Pharma in partnership with AstraZeneca, is one of the most advanced CD39-targeted programs. The Phase II MATISSE study is evaluating IPH5201 with durvalumab and platinum-based chemotherapy in patients with previously untreated stage II–IIIA resectable non-small cell lung cancer. Treatment is administered around surgery, connecting CD39 inhibition to a high-value perioperative setting where the objective is to increase tumor clearance and reduce recurrence risk.

A 2026 interim analysis included 40 treated patients and reported an overall pathological complete response rate of 27.5%, with a 95% confidence interval of 14.6% to 43.9%. The rate reached 35.7% among patients with PD-L1 expression of at least 1% and 50.0% among those with PD-L1 expression of at least 50%. Higher baseline densities of CD39-positive and CD8-positive cells were also associated with stronger pathological responses. These findings supported continued enrollment among PD-L1-positive patients. Innate Pharma MATISSE Results

The perioperative setting gives IPH5201 a defined commercial pathway. Demand would be linked to diagnosis, neoadjuvant treatment, surgery, and a limited postoperative course rather than prolonged metastatic therapy. Adoption would involve medical oncologists, thoracic surgeons, pathology teams, infusion centers, and hospital pharmacy committees.

The United States is expected to record 229,410 new lung cancer cases and 124,990 deaths in 2026, while non-small cell lung cancer represents most diagnoses. The commercially relevant population for IPH5201 would be considerably narrower because eligibility depends on resectable disease, stage, treatment fitness, biomarker status, and the final approved label. American Cancer Society Lung Cancer Statistics

 

TTX-030 Makes Pancreatic Cancer a Critical Validation Market

TTX-030 is being advanced by Trishula Therapeutics in collaboration with AbbVie. Its development is commercially important because pancreatic cancer has a high mortality burden and limited responsiveness to most immunotherapy approaches. The program is testing whether CD39 blockade can make the pancreatic tumor environment more responsive when combined with standard chemotherapy.

In a Phase I study involving 57 efficacy-evaluable patients, mainly with first-line metastatic pancreatic ductal adenocarcinoma, the sponsor reported a 30% objective response rate, median progression-free survival of 7.5 months, and median overall survival of 19.1 months. Three complete responses were recorded. These results supported progression into randomized development. Trishula TTX-030 Results

The same study identified a potentially important HLA-DQ-high subgroup. Among 28 patients with high HLA-DQ expression, the objective response rate reached 46%, median progression-free survival was 9.6 months, and median overall survival was 21.9 months. This finding influenced the design of the ELTIVATE study, which was planned to enroll approximately 180 patients across three treatment arms and assess progression-free survival in the HLA-DQ-high population.

Randomized evidence from ELTIVATE is a major value inflection point for the market. Positive results would support the use of HLA-DQ as a patient-selection tool, strengthen confidence in CD39 biology, and improve the commercial value of related programs. Weak results would make broad pancreatic cancer positioning more difficult and increase pressure on developers to focus on narrower biomarker-defined populations.

The United States is expected to record about 67,530 new pancreatic cancer cases and 52,740 deaths in 2026. The eligible population for a TTX-030-based regimen would depend on metastatic status, pancreatic ductal histology, treatment line, chemotherapy suitability, performance status, and biomarker eligibility. NCI SEER Pancreatic Cancer Statistics

 

ES014 Creates a Bispecific and Orphan-Disease Opportunity

Elpiscience is differentiating its pipeline through ES014, a bispecific biologic targeting both CD39 and transforming growth factor beta. The construct is designed to address two immune-suppression pathways through one investigational product. Its development has included non-small cell lung cancer, gastrointestinal stromal tumors, desmoid tumors, and other advanced solid tumors.

Phase I data presented in 2025 covered 75 treated patients. The study included 43 patients with non-small cell lung cancer, 10 with gastrointestinal stromal tumors, five with desmoid tumors, and 17 with other cancers. Within the five-patient desmoid tumor cohort, two partial responses and three cases of stable disease produced a reported objective response rate of 40% and disease control rate of 100%. Elpiscience ES014 Phase I Results

The FDA granted ES014 orphan drug designation for desmoid tumors in February 2026, and Elpiscience initiated a focused Phase II study in China in May 2026. This gives ES014 a more concentrated development path than programs pursuing broad solid-tumor populations. Desmoid tumors are treated in specialist centers, which could support a focused commercial model with limited sales-force requirements and stronger physician concentration. FDA Orphan Drug Record

The rare-disease route also provides greater differentiation, although ES014 will face an established treatment environment. Nirogacestat is already approved in the United States for adults with progressing desmoid tumors requiring systemic treatment. ES014 will need to demonstrate a clear benefit in efficacy, durability, tolerability, sequencing, or patient selection to secure a commercially relevant position.

 

Monoclonal Antibodies Lead the Therapeutic Format

Monoclonal antibodies represent the dominant development format in the CD39 targeted therapies market. IPH5201, TTX-030, AB598, ES002023, PUR001, JS019, and the discontinued SRF617 program have all been developed as antibody-based therapies. Antibodies fit existing oncology infusion pathways and can provide prolonged target engagement, making them suitable for combination with chemotherapy and checkpoint inhibitors.

Bispecific antibodies are emerging as the main source of format differentiation. ES014 combines CD39 inhibition with TGF-beta blockade, while additional early programs are exploring CD39 alongside other immune targets. These constructs may reduce the need to administer two separate experimental biologics, but they also require developers to manage more complex manufacturing, dosing, and safety profiles.

Small-molecule CD39 inhibition remains less advanced clinically than antibody development. Several compounds used in laboratory research are non-selective and unsuitable as commercial medicines. AB680 is sometimes incorrectly grouped with CD39 inhibitors, but it targets CD73. The current clinical market is therefore primarily biologic-driven.

 

Biomarker Strategy Will Determine the Treatable Population

The market does not yet have a standardized CD39 companion diagnostic or a single definition of a CD39-responsive patient. Different programs are using different selection and enrichment approaches. MATISSE has evaluated PD-L1 expression and the density of CD39-positive and CD8-positive cells. TTX-030 is focusing on HLA-DQ expression. ES014 has explored tumor CD39 expression across several cohorts.

This variation has direct commercial consequences. A validated biomarker could improve trial success rates, reduce treatment among patients unlikely to benefit, and strengthen payer acceptance. It could also reduce the eligible patient population, making market value more dependent on price, treatment duration, and response concentration.

Diagnostic companies and pathology laboratories may gain a supporting role if regulators require a companion or complementary test. Commercial adoption would then depend on assay reproducibility, tissue availability, turnaround time, reimbursement, and the ability of hospitals to integrate testing into routine oncology workflows.

The absence of a common biomarker threshold also prevents cancer incidence data from being converted directly into a reliable addressable market. Final demand will depend on tumor type, stage, treatment line, prior therapy, performance status, biomarker eligibility, physician preference, reimbursement, and competition from approved regimens.

 

Licensing Agreements Reveal the Current Value Pool

Innate Pharma’s collaboration with AstraZeneca provides the strongest disclosed commercial signal in the market. The agreement includes potential payments of up to USD 885 million and double-digit royalties on future sales, while Innate Pharma had received USD 60 million under the arrangement by its 2026 disclosure. The deal reflects the strategic value assigned to IPH5201 and AstraZeneca’s interest in integrating CD39 blockade with durvalumab. Innate Pharma IPH5201 Partnership

Arcus Biosciences obtained exclusive worldwide rights to anti-CD39 antibodies from WuXi Biologics. Its public filing disclosed up to USD 14 million in additional clinical and regulatory milestone obligations and low-single-digit royalties on potential future sales. These arrangements show how value currently flows through intellectual-property licensing, milestone economics, and development partnerships.

Trishula’s collaboration with AbbVie gives TTX-030 access to a major pharmaceutical partner and an investigational PD-1 antibody. Elpiscience is creating value through internal clinical execution, bispecific differentiation, and a focused orphan-development strategy. Competitive strength is therefore measured through financing, trial quality, combination access, biomarker strategy, and partner support rather than commercial market share.

 

Portfolio Decisions Remain a Major Competitive Risk

The termination of SRF617 demonstrates the capital-allocation risk surrounding CD39 programs. Surface Oncology paused development for business considerations before the program was eventually recorded as terminated. The decision showed that a scientifically credible target does not guarantee continued investment when early clinical differentiation is limited or company priorities change.

Other candidates face similar pressure. Development costs rise sharply when programs move from dose-escalation studies into randomized Phase II and Phase III trials. Companies must fund drug manufacturing, global clinical sites, biomarker testing, combination products, and long follow-up periods. Smaller developers remain dependent on partnerships, licensing transactions, or additional financing to maintain progress.

Partner dependence creates another risk. A large pharmaceutical company may change development priorities, reduce trial scope, or discontinue an asset after reviewing competitive data. Programs with clear indication focus, measurable biomarkers, and early evidence of incremental benefit are more likely to retain funding.

 

Market Outlook

The CD39 targeted therapies market is moving from target validation toward indication-specific clinical competition. IPH5201 has established the strongest recent perioperative signal, TTX-030 represents the most important randomized pancreatic cancer test, ES014 offers a differentiated bispecific and orphan-disease strategy, and AB598 maintains competition from a broader immuno-oncology platform.

The next phase of market growth will be determined by randomized efficacy, biomarker reproducibility, safety in combination regimens, regulatory progress, and the ability to demonstrate value beyond existing treatments. Developers that identify responsive patient groups and secure strong pharmaceutical partnerships will have the clearest commercial advantage.

Competition will remain centered on clinical assets rather than sales share until the first therapy receives approval. Trial results, licensing milestones, biomarker validation, and indication expansion will continue to define market value during the forecast period.

 

Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 498.54 Million
Revenue Forecast in 2032	USD 1.48 Billion
Overall Growth Rate	CAGR of 16.8% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
By Therapy Type	Monoclonal Antibodies; Bispecific Antibodies; Small-Molecule Inhibitors
By Cancer Indication	Non-Small Cell Lung Cancer; Pancreatic Cancer; Gastrointestinal Stromal Tumors; Desmoid Tumors; Other Solid Tumors
By Treatment Approach	Monotherapy; Combination Immunotherapy; Combination Chemotherapy; Perioperative Therapy
By End User	Hospitals; Specialty Cancer Centers; Research Institutes; Clinical Trial Centers
By Geography	North America; Europe; Asia-Pacific; Latin America; Middle East & Africa
Market Drivers – Growth of Immuno-Oncology Combination Strategies	Increasing development of combination therapies with immune checkpoint inhibitors and chemotherapy is supporting investment in CD39 blockade approaches.
Market Drivers – Biomarker-Based Precision Oncology Development	Growing focus on patient selection strategies using biomarkers such as CD39 expression, PD-L1 status, and HLA-DQ profiles is shaping clinical adoption potential.
Market Drivers – Pharmaceutical Partnerships and Pipeline Expansion	Strategic collaborations, licensing agreements, and oncology pipeline investments are accelerating development of CD39-targeted candidates.
Customization Option	Available upon request